Cancer Biomarkers Market Size by Profiling Technology (Omics, Imaging), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Product (Instruments, Consumables), Application (Diagnostics, R&D, Prognostics), Enduser, and Region - Global Forecast to 2029
Report Code: MD 5627 Apr, 2024, by marketsandmarkets.com
The size of global cancer biomarkers market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at a CAGR of 11.3% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
The primary drivers of growth in this market are the rising incidence of cancer worldwide, growing research on cancer biomarkers, growing usage of biomarkers in drug discovery and development, and technical developments.
Attractive Opportunities in the Cancer Biomarker Market
To know about the assumptions considered for the study, Request for Free Sample Report
Cancer Biomarkers Market Dynamics
Driver: Rising technological advancements in the development of cancer biomarkers
Advancements in omics technologies enable faster acquisition of genomics, proteomics, and metabolomics data and its integration with clinical trial data using advanced bioinformatics software. The omics revolution in the last decade has increased the applications of cancer biomarkers in cancer research. Also, developments in high-throughput genomic technologies facilitate identifying and analyzing mutations and polymorphisms in key genes, thus expanding the spectrum of available genomic biomarkers. The advancements in arrays and proteomics technologies have addressed the challenges in identifying and understanding the functions and interactions of various proteins. These technological advancements have simplified the process of discovery & development of novel cancer biomarkers to a great extent.
Restraint: Technical issues related to sample collection & storage
Cancer biomarkers are widely used in epidemiology studies to examine various phases of human disease. In order to minimize future research expenditures using banked samples and extract a great deal of information from a small number of samples, this calls for cautious handling and storage of priceless biological samples. Therefore, one of the most important concerns for service providers is sample collection, which is followed by sample access. These samples must undergo strict quality control, and proper storage must be provided to prevent loss. Additionally, various samples are needed for the procedures of risk assessment, screening, diagnosis, and monitoring.
Opportunity: Personalized medicine
Personalized medicine determines which course of treatment is best for each patient. In certain facets of personalized medicine, cancer biomarkers are crucial. The detection of these illnesses is made possible by the consumables used in cancer biomarker testing. Diagnostic tools for cancer biomarkers are being utilized in conjunction with a number of experimental treatments. Therefore, it is anticipated that companies involved in the cancer biomarkers market will have chances for growth in the personalized medicine space.
Challenge: Challenges associated with cancer biomarker validation
As part of the validation process for cancer biomarkers, assays are assessed and performance metrics like repeatability, sensitivity, and specificity are measured. In order to establish cancer biomarkers as trustworthy instruments to assist research, healthcare, and biopharma investment decisions, validation is essential. However, businesses, particularly small ones, are quite concerned about the significant expenses associated with cancer biomarker validation. Moreover, the validation procedure for cancer biomarkers is complicated by the intrinsic fluctuation in biomarker levels and molecular heterogeneity. The time necessary for test development is another issue, which makes it difficult to create assays quickly enough to keep up with the production of biomarkers.
The cancer biomarker market is moderately consolidated. The top players— F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), CENTOGENE N.V. (Germany), BioGenex (India), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), and INOVIQ Ltd. (Australia) in the cancer biomarker market accounted for a combined majority market share in 2023. The companies in the sector are fiercely competitive.
Cancer Biomarker Ecosystem/Market Map
In 2023, omics technologies segment accounted for the largest share in the cancer biomarkers industry, by profiling technologies
The cancer biomarkers market has been divided into two segments based on profiling methods: omics technologies and imaging technologies. Due primarily to the growing usage of cancer biomarkers in drug discovery and development as well as the rapid growth of technology in the field of cancer biomarker creation, the omics technology segment held the highest share of the market in 2023.
In 2023, breast cancer segment accounted for the largest share of the cancer biomarkers industry, by cancer type
The cancer biomarkers market is divided into categories according on the kind of cancer, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, and other cancer types. 2020 saw the highest percentage go to the breast cancer section. The rise is driven by factors like the rising incidence of cancer worldwide.
In 2023, instruments segment accounted for the largest share in the cancer biomarkers industry, by product
Based on product, the cancer biomarkers market is classified into consumables, instruments, and bioinformatics software. Due to the growing need for cancer detection and the number of technical breakthroughs, the instruments sector held a dominant position in this market in 2023.
In 2023, diagnostics segment accounted for the largest share in the cancer biomarkers industry, by application
The cancer biomarkers market has been segmented into diagnostics, research & development, prognostics, risk assessment and other applications. As of 2023, the market was dominated by the diagnostics sector. The market will rise as a result of more cancer biomarkers being used for companion diagnostics.
In 2023, diagnostic laboratories segment accounted for the largest share in the cancer biomarkers industry, by end-user
Based on end user, the cancer biomarker market is segmented into diagnostic laboratories, Biopharmaceutical Companies & CROs, research and academic institutes and other end-users. By 2023, the market for cancer biomarkers was dominated by the diagnostic laboratories segment. The rising prevalence of cancer and the expanding number of clinical laboratories conducting cancer biomarker-based diagnostics tests globally are the main causes of this end-user segment's size.
North America is the largest regional market for cancer biomarkers industry
The global cancer biomarkers market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America held the most market share for cancer biomarkers worldwide in 2023. The expansion of the North American market may be ascribed to the relationship between rising population and rising levels of research.
To know about the assumptions considered for the study, download the pdf brochure
The major players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US). The market leadership of these players stems from their comprehensive product portfolios and expanding global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.
Scope of the Cancer Biomarkers Industry
|
Report Metric |
Details |
|
Market Revenue Size in 2024 |
$24.5 billion |
|
Projected Revenue Size by 2029 |
$42.0 billion |
|
Industry Growth Rate |
Poised to Grow at a CAGR of 11.3% |
|
Market Driver |
Rising technological advancements in the development of cancer biomarkers |
|
Market Opportunity |
Personalized medicine |
This report categorizes the cancer biomarker market to forecast revenue and analyze trends in each of the following submarkets:
By Profiling Technology
-
Omics Technologies
- Proteomics
- Genomics
- Other Omics Technologies
-
Imaging Technologies
- Ultrasound Imaging
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Positron Emission Tomography (PET)
- Mammography
By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Leukemia
- Thyroid Cancer
- Bladder Cancer
- Non-Hodgkin's Lymphoma
- Kidney Cancer
- Other Cancer Types
By Product
- Instrument
- Consumables
- Bioinformatics Software
By Application
- Diagnostics
- Research & Development
- Prognostics
- Risk Assessment
- Other Applications
By Enduser
- Diagnostic Laboratories
- Biopharmaceutical Companies & CROs
- Research and Academic Institutes
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
-
Middle East Africa
- GCC Countries
Recent Developments of Cancer Biomarkers Industry:
- In November 2023, Agilent received FDA approval for PD-L1 IHC 22C3 pharmDx in gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- In May 2022, Illumina introduced a new pan-cancer companion diagnostic to match patients with rare genetic mutations to targeted therapy.
- In December 2022, QIAGEN received FDA approval for a companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global cancer biomarkers market?
The global cancer biomarkers market boasts a total revenue value of $42.0 billion by 2029.
What is the estimated growth rate (CAGR) of the global cancer biomarkers market?
The global cancer biomarkers market has an estimated compound annual growth rate (CAGR) of 11.3% and a revenue size in the region of $24.5 billion in 2024. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 31)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 CANCER BIOMARKERS MARKET SEGMENTATION
FIGURE 2 REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 37)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 3 CANCER BIOMARKERS INDUSTRY: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 8 MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 STUDY ASSUMPTIONS
2.7 RISK ASSESSMENT
2.7.1 RISK ASSESSMENT: MARKET
2.8 GROWTH RATE ASSUMPTIONS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 50)
FIGURE 10 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 11 CANCER BIOMARKERS INDUSTRY, BY CANCER TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 12 MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 15 MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 55)
4.1 CANCER BIOMARKERS MARKET OVERVIEW
FIGURE 16 TECHNOLOGICAL ADVANCEMENTS IN CANCER BIOMARKERS TO DRIVE MARKET
4.2 CANCER BIOMARKERS INDUSTRY SHARE, BY PROFILING TECHNOLOGY, 2024 VS. 2029
FIGURE 17 OMICS TECHNOLOGIES TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 MARKET SHARE, BY CANCER TYPE, 2024 VS. 2029
FIGURE 18 LUNG CANCER SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2029
4.4 MARKET SHARE, BY PRODUCT, 2024 VS. 2029
FIGURE 19 INSTRUMENTS SEGMENT TO DOMINATE MARKET IN 2024
4.5 MARKET SHARE, BY APPLICATION, 2024 VS. 2029
FIGURE 20 DIAGNOSTICS SEGMENT TO DOMINATE MARKET IN 2029
4.6 MARKET SHARE, BY END USER, 2024 VS. 2029
FIGURE 21 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.7 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 59)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 CANCER BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Technological advancements in cancer biomarkers
5.2.1.2 Increasing incidence of cancer
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015–2035
5.2.1.3 Rising use of cancer biomarkers in drug discovery & development
5.2.1.4 Increasing R&D on cancer biomarkers
5.2.2 RESTRAINTS
5.2.2.1 Technical issues related to sample collection and storage
5.2.2.2 High capital investments and extensive timelines for development of cancer biomarkers
TABLE 4 TIMEFRAME FOR DEVELOPMENT OF BIOMARKERS
5.2.2.3 Unfavorable regulatory and reimbursement scenarios
5.2.3 OPPORTUNITIES
5.2.3.1 Personalized medicine
FIGURE 24 WORKFLOW FOR PERSONALIZED TREATMENT
FIGURE 25 PERCENTAGE OF CANCER CLINICAL TRIALS INCORPORATING CANCER BIOMARKERS
5.2.3.2 Growing applications of companion diagnostics
TABLE 5 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS
5.2.3.3 Emerging economies
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with cancer biomarker validation
5.2.4.2 Shortage of skilled professionals
5.3 PRICING ANALYSIS
5.3.1 PRICING MODEL ANALYSIS
TABLE 6 INDICATIVE PRICING FOR CANCER BIOMARKER PRODUCTS (2023)
TABLE 7 AVERAGE SELLING PRICE OF CANCER BIOMARKER PRODUCTS, BY REGION
5.4 PATENT ANALYSIS
5.4.1 PATENT ANALYSIS OF CANCER BIOMARKERS INDUSTRY
FIGURE 26 PATENT ANALYSIS FOR CANCER BIOMARKERS (JANUARY 2014–DECEMBER 2023)
5.5 VALUE CHAIN ANALYSIS
FIGURE 27 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 28 MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS OF MARKET
FIGURE 29 MARKET: ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 8 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY ANALYSIS
5.9.1 INTRODUCTION
5.9.2 CANCER BIOMARKERS QUALIFICATION IN US
5.9.3 CANCER BIOMARKERS QUALIFICATION IN EU
FIGURE 30 MARKET: EMA QUALIFICATION PROCEDURE
5.9.4 CANCER BIOMARKERS ACCEPTANCE IN DRUG DEVELOPMENT IN EU AND US
5.9.5 EMA APPROVALS
5.9.6 FDA APPROVALS
5.10 TRADE ANALYSIS
5.11 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
5.12 TECHNOLOGY ANALYSIS
5.13 KEY TECHNOLOGIES
5.13.1 POLYMERASE CHAIN REACTION
5.13.2 NEXT-GENERATION SEQUENCING
5.14 COMPLEMENTARY TECHNOLOGIES
5.14.1 IN SITU HYBRIDIZATION
5.15 ADJACENT TECHNOLOGIES
5.15.1 IMMUNOHISTOCHEMISTRY
5.16 KEY CONFERENCES & EVENTS IN 2024–2025
TABLE 11 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.17.1 REVENUE SHIFT & REVENUE POCKETS FOR MARKET
FIGURE 31 REVENUE SHIFT FOR MARKET
5.18 KEY STAKEHOLDERS & BUYING CRITERIA
5.18.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CANCER BIOMARKER PRODUCTS
5.18.2 BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
TABLE 13 KEY BUYING CRITERIA FOR CANCER BIOMARKER PRODUCTS
5.19 CASE STUDY ANALYSIS
5.19.1 CASE STUDY: CASE OF OVARIAN CANCER TO ILLUSTRATE BEST PRACTICE IN MACHINE LEARNING AND SHAPLEY ANALYSIS
5.20 INVESTMENT & FUNDING SCENARIO
TABLE 14 US: CANCER BIOMARKERS FUNDING BY VARIOUS INSTITUTES/CENTERS, 2021–2024
6 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY (Page No. - 86)
6.1 INTRODUCTION
TABLE 15 CANCER BIOMARKERS INDUSTRY, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
6.2 OMICS TECHNOLOGIES
TABLE 16 MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 17 MARKET FOR OMICS TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
6.2.1 PROTEOMICS
TABLE 18 MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 19 MARKET FOR PROTEOMICS, BY REGION, 2022–2029 (USD MILLION)
6.2.1.1 Immunoassays
6.2.1.1.1 Facilitate diagnosis of cancer at early stage
TABLE 20 IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.2 Mass spectrometry
6.2.1.2.1 High specificity of mass spectroscopy to drive adoption
TABLE 21 MASS SPECTROMETRY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.3 2D gel electrophoresis
6.2.1.3.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive segment
TABLE 22 2D GEL ELECTROPHORESIS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.4 Protein microarrays
6.2.1.4.1 Increasing demand for gel electrophoresis in proteomics research and personalized medicine to drive growth
TABLE 23 PROTEIN MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.1.5 Other proteomic technologies
TABLE 24 OTHER PROTEOMIC TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2 GENOMICS
TABLE 25 MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 26 MARKET FOR GENOMICS, BY REGION, 2022–2029 (USD MILLION)
6.2.2.1 Next-generation sequencing
6.2.2.1.1 Development of advanced NGS platforms by leading players to drive growth
TABLE 27 NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2.2 Polymerase chain reaction
6.2.2.2.1 Cost-effectiveness and easy availability of PCR tests to propel market
TABLE 28 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.2.3 In situ hybridization
6.2.2.3.1 ISH-based diagnostic tests help identify specific biomarkers in clinical trials
TABLE 29 IN SITU HYBRIDIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2.3 OTHER OMICS TECHNOLOGIES
TABLE 30 MARKET FOR OTHER OMICS TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
6.3 IMAGING TECHNOLOGIES
TABLE 31 MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 32 MARKET FOR IMAGING TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
6.3.1 ULTRASOUND IMAGING
6.3.1.1 Use of ultrasound for biomarker research in understanding disease onset & progression to drive growth
TABLE 33 ULTRASOUND IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2 COMPUTED TOMOGRAPHY
6.3.2.1 Technological advancements to drive adoption
TABLE 34 COMPUTED TOMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.3 MAGNETIC RESONANCE IMAGING
6.3.3.1 Growing preference for open MRIs to support market growth
TABLE 35 MAGNETIC RESONANCE IMAGING MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.4 POSITRON EMISSION TOMOGRAPHY
6.3.4.1 Development of lab-on-chip-based multiplex assays to propel market
TABLE 36 POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.5 MAMMOGRAPHY
6.3.5.1 Advanced technologies like 3D mammography to support market growth
TABLE 37 MAMMOGRAPHY MARKET, BY REGION, 2022–2029 (USD MILLION)
7 CANCER BIOMARKERS MARKET, BY CANCER TYPE (Page No. - 108)
7.1 INTRODUCTION
TABLE 38 CANCER BIOMARKERS INDUSTRY, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 39 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040
7.2 BREAST CANCER
7.2.1 INCREASING PREVALENCE OF BREAST CANCER TO DRIVE MARKET
TABLE 40 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 41 MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION)
7.3 LUNG CANCER
7.3.1 INCREASING FOCUS ON DEVELOPMENT OF LUNG CANCER BIOMARKERS TO SUPPORT MARKET GROWTH
TABLE 42 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 43 MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
7.4 COLORECTAL CANCER
7.4.1 RISING DEMAND FOR BIOMARKERS IN EARLY DIAGNOSIS & PROGNOSIS OF COLORECTAL CANCER TO DRIVE MARKET
TABLE 44 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
TABLE 45 MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION)
7.5 PROSTATE CANCER
7.5.1 ADVANCEMENTS IN GENOMIC TECHNOLOGIES TO PROPEL MARKET
TABLE 46 MARKET FOR PROSTATE CANCER, BY REGION, 2022–2029 (USD MILLION)
7.6 MELANOMA
7.6.1 INCREASING UTILIZATION OF DIAGNOSTICS IN BRAF INHIBITOR THERAPY TO DRIVE MARKET
TABLE 47 ESTIMATED NUMBER OF MELANOMA CASES, BY REGION, 2022 VS. 2040
TABLE 48 MARKET FOR MELANOMA, BY REGION, 2022–2029 (USD MILLION)
7.7 LEUKEMIA
7.7.1 INCREASING NUMBER OF RESEARCH STUDIES FOR DEVELOPMENT OF ACCURATE DIAGNOSTIC METHODS FOR LEUKEMIA TO DRIVE MARKET
TABLE 49 MARKET FOR LEUKEMIA, BY REGION, 2022–2029 (USD MILLION)
7.8 THYROID CANCER
7.8.1 INCREASING RESEARCH FOR IDENTIFICATION OF NEW BIOMARKERS FOR THYROID NODULES TO SUPPORT MARKET GROWTH
TABLE 50 MARKET FOR THYROID CANCER, BY REGION, 2022–2029 (USD MILLION)
7.9 BLADDER CANCER
7.9.1 INCREASING APPROVALS OF URINARY BIOMARKERS FOR DETECTION OF BLADDER CANCER TO PROPEL MARKET
TABLE 51 MARKET FOR BLADDER CANCER, BY REGION, 2022–2029 (USD MILLION)
7.1 NON-HODGKIN’S LYMPHOMA
7.10.1 INCREASING RESEARCH ACTIVITIES ON NHL TO DRIVE MARKET
TABLE 52 MARKET FOR NON-HODGKIN’S LYMPHOMA, BY REGION, 2022–2029 (USD MILLION)
7.11 KIDNEY CANCER
7.11.1 DEVELOPMENT OF NEW TARGETED THERAPIES FOR TREATMENT OF KIDNEY CANCER TO DRIVE MARKET
TABLE 53 MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION)
7.12 OTHER CANCERS
TABLE 54 MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION)
8 CANCER BIOMARKERS MARKET, BY PRODUCT (Page No. - 122)
8.1 INTRODUCTION
TABLE 55 CANCER BIOMARKERS INDUSTRY, BY PRODUCT, 2022–2029 (USD MILLION)
8.2 INSTRUMENTS
TABLE 56 CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 57 CANCER BIOMARKER INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.1 IMAGING INSTRUMENTS
8.2.1.1 Technological advancements in imaging instruments to drive growth
TABLE 58 IMAGING INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.2 PATHOLOGY-BASED INSTRUMENTS
8.2.2.1 Rising demand for cancer diagnosis to drive market
TABLE 59 PATHOLOGY-BASED INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.2.3 BIOPSY INSTRUMENTS
8.2.3.1 Increasing prevalence of cancer to drive growth
TABLE 60 BIOPSY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3 CONSUMABLES
TABLE 61 CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 62 CANCER BIOMARKER CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.1 ANTIBODIES
8.3.1.1 Increasing approvals for therapeutic antibodies by regulatory authorities to drive market
TABLE 63 ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.2 KITS & REAGENTS
8.3.2.1 Ease of use to support adoption
TABLE 64 KITS & REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
8.3.3 PROBES
8.3.3.1 Need for probes in assay tests for cancer detection to support market growth
TABLE 65 PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
8.4 BIOINFORMATICS SOFTWARE
8.4.1 TECHNOLOGICAL ADVANCEMENTS AND GROWING INFORMATION TECHNOLOGY SECTOR TO DRIVE MARKET
TABLE 66 CANCER BIOMARKER BIOINFORMATICS SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
9 CANCER BIOMARKERS MARKET, BY APPLICATION (Page No. - 131)
9.1 INTRODUCTION
TABLE 67 CANCER BIOMARKERS INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 DIAGNOSTICS
9.2.1 INCREASED AWARENESS & ACCEPTANCE OF TECHNOLOGICALLY ADVANCED BIOMARKER PRODUCTS TO PROPEL MARKET
TABLE 68 MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.3 RESEARCH & DEVELOPMENT
9.3.1 INCREASING FOCUS OF PHARMACEUTICAL COMPANIES ON USE OF BIOMARKERS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET
TABLE 69 MARKET FOR RESEARCH & DEVELOPMENT APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.4 PROGNOSTICS
9.4.1 GROWING ADOPTION OF SPECIFIC AND SENSITIVE BIOMARKER TESTS TO SUPPORT MARKET GROWTH
TABLE 70 MARKET FOR PROGNOSTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.5 RISK ASSESSMENT
9.5.1 USED FOR DETECTING MUTATIONS OR VARIANTS IN GERMLINE DNA OF INDIVIDUALS
TABLE 71 MARKET FOR RISK ASSESSMENT APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 72 MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
10 CANCER BIOMARKERS MARKET, BY END USER (Page No. - 138)
10.1 INTRODUCTION
TABLE 73 CANCER BIOMARKERS INDUSTRY, BY END USER, 2022–2029 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE GROWTH
TABLE 74 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
10.3 BIOPHARMACEUTICAL COMPANIES AND CROS
10.3.1 RISING FOCUS ON DRUG DISCOVERY IN BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO DRIVE MARKET
TABLE 75 MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2022–2029 (USD MILLION)
10.4 RESEARCH AND ACADEMIC INSTITUTES
10.4.1 INCREASING RESEARCH FUNDING FOR EARLY DIAGNOSIS TO AUGMENT MARKET
TABLE 76 MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
10.5 OTHER END USERS
TABLE 77 MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
11 CANCER BIOMARKERS MARKET, BY REGION (Page No. - 145)
11.1 INTRODUCTION
TABLE 78 CANCER BIOMARKERS INDUSTRY, BY REGION, 2022–2029 (USD MILLION)
11.2 NORTH AMERICA
TABLE 79 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY CANCER TYPE, 2022
FIGURE 34 NORTH AMERICA: CANCER BIOMARKERS MARKET SNAPSHOT
TABLE 80 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 83 NORTH AMERICA: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 85 NORTH AMERICA: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 86 NORTH AMERICA: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 87 NORTH AMERICA: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 88 NORTH AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 89 NORTH AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 91 NORTH AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.1 NORTH AMERICA: RECESSION IMPACT
11.2.2 US
11.2.2.1 Increasing use of cancer biomarkers for cancer treatment to drive market
TABLE 92 KEY GROWTH STRATEGIES BY LEADING PLAYERS FOR DEVELOPMENT OF CANCER BIOMARKERS
TABLE 93 US: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 94 US: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 95 US: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 96 US: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 US: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 98 US: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 99 US: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 100 US: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 101 US: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 US: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 103 US: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 104 US: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing government initiatives for discovery and development of cancer biomarkers to drive growth
TABLE 105 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 106 CANADA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 107 CANADA: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 CANADA: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 109 CANADA: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 110 CANADA: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 CANADA: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 112 CANADA: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 113 CANADA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 114 CANADA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 115 CANADA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 116 CANADA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3 EUROPE
TABLE 117 EUROPE: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 119 EUROPE: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 120 EUROPE: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 121 EUROPE: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 122 EUROPE: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 EUROPE: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 124 EUROPE: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 125 EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 126 EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 127 EUROPE: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 128 EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.1 EUROPE: RECESSION IMPACT
11.3.2 GERMANY
11.3.2.1 Favorable government health policies to drive market
TABLE 129 GERMANY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 130 GERMANY: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 131 GERMANY: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 132 GERMANY: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 GERMANY: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 GERMANY: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 135 GERMANY: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 136 GERMANY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 137 GERMANY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 138 GERMANY: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 139 GERMANY: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Availability of government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
TABLE 140 UK: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 141 UK: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 142 UK: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 143 UK: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 UK: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 145 UK: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 146 UK: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 147 UK: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 148 UK: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 149 UK: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 150 UK: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Increasing government investments in genomics & proteomics research to drive market
TABLE 151 FRANCE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 152 FRANCE: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 153 FRANCE: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 154 FRANCE: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 FRANCE: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 156 FRANCE: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 157 FRANCE: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 158 FRANCE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 159 FRANCE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 FRANCE: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 161 FRANCE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Growing geriatric population to support market growth
TABLE 162 ITALY: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 163 ITALY: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 164 ITALY: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 ITALY: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 166 ITALY: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 167 ITALY: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 168 ITALY: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 169 ITALY: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 ITALY: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 171 ITALY: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 172 ITALY: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Increasing focus on personalized medicine to propel market
TABLE 173 SPAIN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 174 SPAIN: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 SPAIN: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 176 SPAIN: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 177 SPAIN: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 SPAIN: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 179 SPAIN: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 180 SPAIN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 181 SPAIN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 182 SPAIN: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 183 SPAIN: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 184 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 185 REST OF EUROPE: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 REST OF EUROPE: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 187 REST OF EUROPE: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 188 REST OF EUROPE: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 189 REST OF EUROPE: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 190 REST OF EUROPE: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 191 REST OF EUROPE: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 192 REST OF EUROPE: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 193 REST OF EUROPE: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 194 REST OF EUROPE: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 35 ASIA PACIFIC: CANCER BIOMARKERS MARKET SNAPSHOT
TABLE 195 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 196 ASIA PACIFIC: MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 197 ASIA PACIFIC: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 198 ASIA PACIFIC: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 ASIA PACIFIC: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 ASIA PACIFIC: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 ASIA PACIFIC: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 202 ASIA PACIFIC: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 203 ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 205 ASIA PACIFIC: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.1 ASIA PACIFIC: RECESSION IMPACT
11.4.2 CHINA
11.4.2.1 Advancements in healthcare facilities to drive market
TABLE 207 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 208 CHINA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 209 CHINA: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 CHINA: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 211 CHINA: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 212 CHINA: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 CHINA: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 214 CHINA: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 215 CHINA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 216 CHINA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 CHINA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 218 CHINA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Research initiatives to support market growth
TABLE 219 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 220 JAPAN: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 221 JAPAN: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 222 JAPAN: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 223 JAPAN: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 JAPAN: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 JAPAN: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 226 JAPAN: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 227 JAPAN: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 JAPAN: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 JAPAN: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 230 JAPAN: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Increased demand for early cancer diagnosis to drive market
TABLE 231 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040
TABLE 232 INDIA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 233 INDIA: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 INDIA: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 235 INDIA: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 236 INDIA: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 237 INDIA: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 238 INDIA: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 239 INDIA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 240 INDIA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 241 INDIA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 242 INDIA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.5 REST OF ASIA PACIFIC
TABLE 243 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 244 REST OF ASIA PACIFIC: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 245 REST OF ASIA PACIFIC: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 246 REST OF ASIA PACIFIC: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 REST OF ASIA PACIFIC: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 248 REST OF ASIA PACIFIC: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 249 REST OF ASIA PACIFIC: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 250 REST OF ASIA PACIFIC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 253 REST OF ASIA PACIFIC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5 LATIN AMERICA
TABLE 254 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 255 LATIN AMERICA: MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 256 LATIN AMERICA: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 257 LATIN AMERICA: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 258 LATIN AMERICA: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 259 LATIN AMERICA: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 LATIN AMERICA: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 261 LATIN AMERICA: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 262 LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 264 LATIN AMERICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 265 LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.1 LATIN AMERICA: RECESSION IMPACT
11.5.2 BRAZIL
11.5.2.1 Increasing incidence of cancer to drive market
TABLE 266 BRAZIL: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 267 BRAZIL: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 268 BRAZIL: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 269 BRAZIL: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 BRAZIL: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 271 BRAZIL: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 272 BRAZIL: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 273 BRAZIL: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 274 BRAZIL: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 275 BRAZIL: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 276 BRAZIL: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.3 MEXICO
11.5.3.1 Growing medical tourism to fuel demand for cancer diagnostics
TABLE 277 MEXICO: NUMBER OF CANCER CASES, BY CANCER TYPE, 2022
TABLE 278 MEXICO: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 279 MEXICO: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 280 MEXICO: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 MEXICO: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 282 MEXICO: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 283 MEXICO: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 284 MEXICO: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 285 MEXICO: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 286 MEXICO: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 287 MEXICO: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 288 MEXICO: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5.4 REST OF LATIN AMERICA
TABLE 289 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 290 REST OF LATIN AMERICA: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 REST OF LATIN AMERICA: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 REST OF LATIN AMERICA: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 REST OF LATIN AMERICA: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 294 REST OF LATIN AMERICA: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 295 REST OF LATIN AMERICA: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 296 REST OF LATIN AMERICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 297 REST OF LATIN AMERICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 298 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 299 REST OF LATIN AMERICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET
TABLE 300 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 301 MIDDLE EAST & AFRICA: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 MIDDLE EAST & AFRICA: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 303 MIDDLE EAST & AFRICA: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 304 MIDDLE EAST & AFRICA: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 305 MIDDLE EAST & AFRICA: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 306 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 307 MIDDLE EAST & AFRICA: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 308 MIDDLE EAST & AFRICA: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 309 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 310 MIDDLE EAST & AFRICA: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
11.7 GCC
11.7.1 GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
TABLE 311 GCC: CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 312 GCC: MARKET FOR OMICS TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 313 GCC: MARKET FOR PROTEOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 314 GCC: MARKET FOR GENOMICS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 315 GCC: MARKET FOR IMAGING TECHNOLOGIES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 316 GCC: MARKET, BY CANCER TYPE, 2022–2029 (USD MILLION)
TABLE 317 GCC: MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 318 GCC: CANCER BIOMARKER INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 319 GCC: CANCER BIOMARKER CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 320 GCC: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 321 GCC: CANCER BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
11.7.2 GCC: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE (Page No. - 261)
12.1 OVERVIEW
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER BIOMARKERS MARKET
TABLE 322 CANCER BIOMARKERS INDUSTRY: STRATEGIES ADOPTED BY KEY PLAYERS
12.3 REVENUE SHARE ANALYSIS
FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS IN CANCER BIOMARKERS INDUSTRY, 2019–2023 (USD MILLION)
12.4 MARKET SHARE ANALYSIS
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 323 CANCER BIOMARKERS INDUSTRY: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 38 CANCER BIOMARKERS INDUSTRY: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
12.5.5 COMPANY FOOTPRINT
12.5.5.1 Overall company footprint
FIGURE 39 CANCER BIOMARKERS INDUSTRY: OVERALL COMPANY FOOTPRINT
12.5.5.2 Product footprint
TABLE 324 CANCER BIOMARKERS INDUSTRY: PRODUCT FOOTPRINT
12.5.5.3 Profiling technology footprint
TABLE 325 CANCER BIOMARKERS INDUSTRY: PROFILING TECHNOLOGY FOOTPRINT
12.5.5.4 Application footprint
TABLE 326 CANCER BIOMARKERS INDUSTRY: APPLICATION FOOTPRINT
12.5.5.5 Regional footprint
TABLE 327 CANCER BIOMARKERS INDUSTRY: REGIONAL FOOTPRINT
12.6 COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES (2023)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 40 CANCER BIOMARKERS INDUSTRY: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
12.6.5 COMPETITIVE BENCHMARKING
TABLE 328 CANCER BIOMARKERS INDUSTRY: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 329 CANCER BIOMARKERS INDUSTRY: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
12.7 VALUATION AND FINANCIAL METRICS OF CANCER BIOMARKER VENDORS
FIGURE 41 EV/EBITDA OF KEY VENDORS
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 43 PRODUCT/BRAND COMPARATIVE ANALYSIS
12.8.1 F. HOFFMANN-LA ROCHE LTD.
12.8.2 AGILENT TECHNOLOGIES, INC.
12.8.3 QIAGEN
12.8.4 ABBOTT
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
TABLE 330 CANCER BIOMARKERS INDUSTRY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
12.9.2 DEALS
TABLE 331 CANCER BIOMARKERS MARKET: DEALS, JANUARY 2021–MARCH 2024
13 COMPANY PROFILES (Page No. - 276)
(Business overview, Products offered, Recent developments & MnM View)*
13.1 KEY PLAYERS
13.1.1 F. HOFFMANN-LA ROCHE LTD.
TABLE 332 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
TABLE 333 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
TABLE 334 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
TABLE 335 F. HOFFMANN-LA ROCHE LTD.: DEALS
13.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 336 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 337 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
TABLE 338 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 339 THERMO FISHER SCIENTIFIC INC.: DEALS
13.1.3 QIAGEN
TABLE 340 QIAGEN: COMPANY OVERVIEW
FIGURE 46 QIAGEN: COMPANY SNAPSHOT (2023)
TABLE 341 QIAGEN: PRODUCTS & SERVICES OFFERED
TABLE 342 QIAGEN: PRODUCT LAUNCHES & APPROVALS
TABLE 343 QIAGEN: DEALS
13.1.4 BIO-RAD LABORATORIES, INC.
TABLE 344 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 345 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
13.1.5 ILLUMINA, INC.
TABLE 346 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 48 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
TABLE 347 ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
TABLE 348 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 349 ILLUMINA, INC.: DEALS
13.1.6 AGILENT TECHNOLOGIES, INC.
TABLE 350 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 49 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 351 AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
TABLE 352 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 353 AGILENT TECHNOLOGIES, INC.: DEALS
13.1.7 ABBOTT LABORATORIES
TABLE 354 ABBOTT: COMPANY OVERVIEW
FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2023)
TABLE 355 ABBOTT: PRODUCTS & SERVICES OFFERED
13.1.8 BIOMÉRIEUX
TABLE 356 BIOMÉRIEUX: COMPANY OVERVIEW
FIGURE 51 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
TABLE 357 BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED
13.1.9 MERCK KGAA
TABLE 358 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023)
TABLE 359 MERCK KGAA: PRODUCTS & SERVICES OFFERED
TABLE 360 MERCK KGAA: DEALS
TABLE 361 MERCK KGAA: OTHER DEVELOPMENTS
13.1.10 BECTON, DICKINSON AND COMPANY
TABLE 362 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 53 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
TABLE 363 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 MYRIAD GENETICS, INC.
13.2.2 SYSMEX CORPORATION
13.2.3 HOLOGIC, INC.
13.2.4 QUEST DIAGNOSTICS
13.2.5 CENTOGENE N.V.
13.2.6 BIOGENEX
TABLE 364 BIOGENEX: COMPANY OVERVIEW
13.2.7 SIEMENS HEALTHINEERS
13.2.8 EXACT SCIENCES
13.2.9 R&D SYSTEMS, INC.
13.2.10 BIOVISION INC.
13.2.11 OLINK
13.2.12 ASURAGEN, INC.
13.2.13 MESO SCALE DIAGNOSTICS, LLC
13.2.14 INVIVOSCRIBE, INC.
13.2.15 INOVIQ LTD.
14 APPENDIX (Page No. - 330)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
The objective of the study is analyzing the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as acquisitions, product launches, expansions, agreements and partnerships of the leading players, the competitive landscape of the cancer biomarker market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Breakdown of Primary Participants:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
F. Hoffmann-La Roche Ltd. (Switzerland) |
Marketing Manager |
|
Thermo Fisher Scientific, Inc. (US) |
Senior Product Manager |
|
QIAGEN N.V. (Netherlands) |
Marketing Manager |
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the home healthcare market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the cancer biomarker market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global cancer biomarker Market Size: Bottom-Up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Global cancer biomarker Market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Optometry equipment includes an extensive range of products used to assess vision and diagnose disorders associated with the retina (posterior) or cornea (anterior) of the eye. These devices measure refractive errors, identify the power of the intraocular lens (IOL), measure intraocular pressure (IOP), and analyze the field of vision.
Key Stakeholders
- Senior Management
- End User
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global cancer biomarker market by profiling technology, cancer type, product type, application, enduser, and region.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall cancer biomarker market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific and Rest of the World (Latin America, the Middle East & Africa and GCC Countries)
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Available Customizations
MarketsandMarkets offers the following customizations for this market report
Country Information
- Additional country-level analysis of the cancer biomarker market
Company profiles
- Additional five company profiles of players operating in the cancer biomarker market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarker market
Generating Response ...
Growth opportunities and latent adjacency in Cancer Biomarkers Market
Is it possible to share the study on Cancer Biomarkers Market Size, Share, Growth Research Report 2027
In this Cancer Biomarkers Study do you also cover cancer biomarker testing market ?
We want to know about the cancer biomarker companies prevailing in Cancer Biomarkers Market